

Supplemental File Contents

Supplement Table 1.

Prospective study. Ninety-one LN patients recruited at the time of the diagnosis were prospectively followed for 36 months. Anti-SOD2 IgG2 (**b**) and anti-dsDNA IgG2 (**c**) levels were determined every 6 months in the first year and then every 12 months. In both cases, levels were calculated as relative intensity value (RU/ml) given the absence of WHO international standards.

The line in Figure 1c indicates normal limits for anti-dsDNA IgG2

** $p < 0.001$ vs healthy, SLE and LN any other time point;

* $p < 0.001$ vs vs healthy, SLE any other time point;

° $p < 0,001$ vs T₀

Figure S1.

The same data of Figure 1b relative to the LN patients enrolled in the prospective study are here reported as single line for each patient: (**a**) anti-SOD2 levels and (**b**) proteinuria.

Table Suppl. 1. Clinical Data relative to 479 and 573 patients with Lupus nephritis (LN) and systemic lupus erythematosus (SLE) respectively. Both groups were subdivided in 6 sub-groups according to the time (months) elapsed between the onset of disease and recruitment.


	LN	SLE	0-1 (month)		2-12 (month)		13-24 (month)		25-48 (month)		49-96 (month)		>96 (month)	
			LN	SLE	LN	SLE	LN	SLE	LN	SLE	LN	SLE	LN	SLE
Patient	479	573	168	31	38	36	32	32	30	50	69	85	142	339
Sex M n (%)	71(15)	51(9)	25(15)	3(10)	7(18)	8(22)	7(22)	7(22)	10(30)	5(10)	10(14)	5(6)	12(	23(7)
Sex F n (%)	408(85)	522(91)	143(85)	28(90)	31(82)	28(78)	25(78)	25(78)	20(70%)	45(90)	59(86)	80(94)	130	316(93)
Age* Y	39(28-49)	42(31-54)	32(22-43)	24(13-37)	34(23-47)	29(17-48)	39(28-54)	39(24-53)	37(32-44)	28(20-47)	39(28-48)	36(27-45)	45(38-54)	47(38-57)
anti-dsDNA ratio*	1(0.6-2.8)	1(0.5-2)	17(4-28)	11(3-106)	1.8(1-6.9)	1.8 (0.6-14)	0.6(0.3-1.1)	0.8 (0.3-1.2)	1.9(0.8-6.9)	1.2(0.5-5)	1(0.6-2.3)	1.4(0.7-2.1)	1(0.7-1.8)	0.9 (0.5-1.8)
SLEDAI*	7(6-10)	2(0-5)	10(7-11)	6(5-8)	9(7-11)	5(2.5-6)	6(6-8)	4(2-7)	8(6-9)	3(2-5)	6(5-8)	2(0-5)	6(4-9)	3(1-5)
C3*	81(60-101)	91(76-107)	65(46-85)	61(43-86)	78(54-95)	85(73-97)	87(62-109)	88(60-124)	89(66-110)	80(71-105)	87(70-116)	96(80-104)	93(77-107)	93(78-107)
C4*	13(7-20)	14(10-19)	9(5-15)	7(5-13)	15(10-15)	13(9-18)	13(10-23)	13(7-22)	17(10-23)	14(8-22)	16(11-25)	15(10-19)	16(10-21)	15(11-20)
Hystological class														
I n(%)	4(0.8)		0(0)		0(0)		1(3)		1(3)		1(1)		1(1)	
II	23(4.8)		10(6)		1(3)		0(0)		3(10)		4(6)		5(4)	
III	71(15)		26(15)		5(13)		6(19)		3(10)		6(9)		25(18)	
IV	170(35)		58(35)		14(37)		10(31)		14(47)		25(36)		49(35)	

V	120(25)		60(36)		8(21)		7(22)		5(17)		17(25)		23(16)	
VI	2(0.4)		0		0(0)		0(0)		1(3)		0(0)		1(1)	
nd														
Proteinuria* g/die	1(0.3-2.8)	0.1(0.06-0.14)	2.4(1.2-4.3)	0.11(0.1-0.15)	1.4(0.8-2.9)	0.1(0.05-0.1)	0.3(0.1-1.2)	0.1(0.1-0.15)	0.4(0.2-0.6)	0.1(0.1-0.1)	0.2(0.1-0.6)	0.1(0.1-0.1)	0.3(0.1-0.8)	0.1(0.02-0.1)
eGFR* ml/min/1.73m²	97(69-116)	103(91-117)	94(66-117)	126(110-139)	94(83-122)	100(76-128)	102(86-109)	116(99-129)	106(73-116)	105(97-126)	106(82-123)	109(96-117)	94 (63-108)	101(88-111)
Therapy														
Steroids	341(63)	363(63)	119(71)	14(45)	32(84)	10(27)	22(69)	6(19)	25(83)	40(80)	50(72)	59(69)	93(65)	234(69)
CYC/CYA	56(12)	70(12)	28(17)	0(0)	4(10)	8(22)	1(3)	1(3)	4(13)	40(80)	12(17)	4(5)	7(5)	17(5)
MMF/AZA	176(37)	297(52)	24(14)	1(3)	17(45)	0(0)	12(9)	4(12)	19(63)	21(42)	40(58)	24(28)	64(45)	247(73)
Plaquenil	264(55)	363(63)	57(34)	21(68)	20(53)	20(56)	21(65)	21(66)	20(67)	32(64)	44(64)	55(65)	102(72)	214(63)

* = Data are reported as median and interquartile range

Figure Suppl. 1

a



b

